Latest News

Latest News

Clinical Trial Results | 9 October 2026

Clinical Trial Results | 9 October 2026

The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...

read more
Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

When Months Become Days: AI’s Edge in Patient Engagement

When Months Become Days: AI’s Edge in Patient Engagement

Every therapy that reaches a patient first has to clear a quieter hurdle that rarely makes headlines: finding enough of the right people to test it. That hurdle is where most clinical programs stumble. Roughly 80% of clinical trials fail to meet their enrollment...

read more
Workforce Capability Standardization in Medical Affairs

Workforce Capability Standardization in Medical Affairs

For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...

read more
Weekly News Roundup | 06 July 2026

Weekly News Roundup | 06 July 2026

Life science news 6 July 2026: the FDA expands the world’s first CRISPR gene therapy to children as young as two, Ipsen commits up to $1.75 billion for a late-stage blood cancer drug, and two first-in-class FDA approvals reshape the cell therapy landscape in a busy...

read more
Atacicept IgA Nephropathy: FDA Decision Due 7 July

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...

read more
Clinical Trials Roundup | 03 July 2026

Clinical Trials Roundup | 03 July 2026

Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...

read more
FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

read more
Beyond Animal Models: iPSC Assays Unlock the Human Brain

Beyond Animal Models: iPSC Assays Unlock the Human Brain

For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...

read more
When Months Become Days: AI’s Edge in Patient Engagement

When Months Become Days: AI’s Edge in Patient Engagement

Every therapy that reaches a patient first has to clear a quieter hurdle that rarely makes headlines: finding enough of the right people to test it. That hurdle is where most clinical programs stumble. Roughly 80% of clinical trials fail to meet their enrollment...

read more
Workforce Capability Standardization in Medical Affairs

Workforce Capability Standardization in Medical Affairs

For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...

read more
Weekly News Roundup | 06 July 2026

Weekly News Roundup | 06 July 2026

Life science news 6 July 2026: the FDA expands the world’s first CRISPR gene therapy to children as young as two, Ipsen commits up to $1.75 billion for a late-stage blood cancer drug, and two first-in-class FDA approvals reshape the cell therapy landscape in a busy...

read more
Atacicept IgA Nephropathy: FDA Decision Due 7 July

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...

read more
Clinical Trials Roundup | 03 July 2026

Clinical Trials Roundup | 03 July 2026

Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...

read more
FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

read more
Beyond Animal Models: iPSC Assays Unlock the Human Brain

Beyond Animal Models: iPSC Assays Unlock the Human Brain

For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

AI Transparency Gap in SaMD Regulation

AI Transparency Gap in SaMD Regulation

Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...

read more
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...

read more
Weekly News Roundup | 29 June 2026

Weekly News Roundup | 29 June 2026

Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...

read more
Clinical Trials Roundup | 26 June 2026

Clinical Trials Roundup | 26 June 2026

This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...

read more
Beyond the Screen: Why Spinal Care Must Be Symptom-Led

Beyond the Screen: Why Spinal Care Must Be Symptom-Led

In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....

read more

Further News

Lenacapavir NHS Access Stalls as NICE Rejects Twice-Yearly PrEP

Lenacapavir NHS access for HIV prevention has stalled at the first hurdle. NICE published draft guidance on 9 September 2026. It does not recommend the twice-yearly injection as pre-exposure prophylaxis in England. The draft does not question whether the medicine...

The GLP-1 Divide: Who Gets the Best Weight-Loss Drugs, and Who Pays for It

A patient arrived on my ward recently with a story I have heard so many times it no longer surprises me. Her blood sugar had crept back into the danger zone, her blood pressure was climbing, and the weight she had lost over the previous year was almost all back. The...

Clinical Trials Roundup | 11 Sept 2026

Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To

Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...

Partial Clinical Hold Lands on Opakalim Before SK Deal Closes

The US Food and Drug Administration has imposed a partial clinical hold on Biohaven’s epilepsy candidate opakalim. The hold took effect on 4 September 2026. Biohaven disclosed it in a Form 8-K filed on 10 September 2026. The measure stops new enrolment across the...

The Other Half of Innovation

What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board

Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...

Why Hormone Health Knowledge Could Improve Female Staff Retention

The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...

Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate

Full tozorakimab COPD trial results cut exacerbations across the eosinophil spectrum, including below 150 cells, raising UK biologic access questions.

    Section 232 Pharma Tariffs: What Changes on 29 September

    On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

    Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery

    The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...

    Coming Off Weight Loss Injections: The Oral Maintenance Option

    Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.